Comment on: “The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review”

TY - JOUR

T1 - Comment on

T2 - “The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review”

AU - Hanna AL-Shaikh, Rana

AU - Wszolek, Zbigniew K.

N1 - Funding Information: R.H.A. receives partial funding by Mayo Clinic internal research funds and is partially funded by Donald G. and Jodi P. Heeringa Family. Z.K.W. receives partial funding by the Mayo Clinic Center for Regenerative Medicine, the gifts from The Sol Goldman Charitable Trust, and the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as principal investigator or coprincipal investigator on Abbvie, Inc. (M15‐562 and M15‐563), Biogen, Inc. (228PD201) grant, and Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301). He serves as principal investigator on the Mayo Clinic American Parkinson Disease Association Information and Referral Center, and as coprincipal investigator of the Mayo Clinic American Parkinson Disease Association Center for Advanced Research. Funding Information: Funding for this work was provided by the Mayo Clinic Center for Regenerative Medicine and Donald G. and Jodi P. Heeringa Family. The authors declare that there are no conflicts of interest relevant to this work. Funding Information: R.H.A. receives partial funding by Mayo Clinic internal research funds and is partially funded by Donald G. and Jodi P. Heeringa Family. Z.K.W. receives partial funding by the Mayo Clinic Center for Regenerative Medicine, the gifts from The Sol Goldman Charitable Trust, and the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as principal investigator or coprincipal investigator on Abbvie, Inc. (M15-562 and M15-563), Biogen, Inc. (228PD201) grant, and Biohaven Pharmaceuticals, Inc. (BHV4157-206 and BHV3241-301). He serves as principal investigator on the Mayo Clinic American Parkinson Disease Association Information and Referral Center, and as coprincipal investigator of the Mayo Clinic American Parkinson Disease Association Center for Advanced Research. Our research study has been approved by the Mayo Clinic institutional review board committee, and the institutional review board number is 16-009414. Informed consent was obtained from all study participants prior to conducting our research, according to Mayo Clinic institutional review board guidelines. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding for this work was provided by the Mayo Clinic Center for Regenerative Medicine and Donald G. and Jodi P. Heeringa Family. The authors declare that there are no conflicts of interest relevant to this work. R.H.A. receives partial funding by Mayo Clinic internal research funds and is partially funded by Donald G. and Jodi P. Heeringa Family. Z.K.W. receives partial funding by the Mayo Clinic Center for Regenerative Medicine, the gifts from The Sol Goldman Charitable Trust, and the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as principal investigator or coprincipal investigator on Abbvie, Inc. (M15-562 and M15-563), Biogen, Inc. (228PD201) grant, and Biohaven Pharmaceuticals, Inc. (BHV4157-206 and BHV3241-301). He serves as principal investigator on the Mayo Clinic American Parkinson Disease Association Information and Referral Center, and as coprincipal investigator of the Mayo Clinic American Parkinson Disease Association Center for Advanced Research. Funding for this work was provided by the Mayo Clinic Center for Regenerative Medicine and Donald G. and Jodi P. Heeringa Family. The authors declare that there are no conflicts of interest relevant to this work.

PY - 2020/2/1

Y1 - 2020/2/1

KW - Machado Joseph Disease

KW - SCA

KW - ataxia

KW - ethnic diversity

KW - spinocerebellar ataxia

UR - http://www.scopus.com/inward/record.url?scp=85078119485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078119485&partnerID=8YFLogxK

U2 - 10.1002/mdc3.12878

DO - 10.1002/mdc3.12878

M3 - Comment/debate

AN - SCOPUS:85078119485

SN - 2330-1619

VL - 7

SP - 237

EP - 238

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 2

ER -